Latest Aurora inhibitors Stories
ROCKVILLE, Md., Nov. 9, 2010 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced presentations for its Phase 2 oncology drug candidate, ENMD-2076.
NERVIANO, Italy, October 23 /PRNewswire/ -- - First Responses in Solid Tumours Reported. Aurora inhibitors play a key role in cell duplication and are implicated in both the onset and progression of numerous types of tumour.
- totally perplexed and mixed up.